ARCHIVES

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

ASCO 2012: Michael Link’s Presidential Address, and the 2012 Award Winners

June 8, 2012

Translation Of “New Biology” Into Clinical Use Identified By DeVita As NCI’s Major Challenge

August 16, 1985

FDA, HCFA Form Council On Biomedical Imaging.

November 10, 2000

In Brief: NCI Scientists May Run For Congress; Upton Back Heroin For Terminal Cancer Patients

September 9, 1977

HAI Delivery Extends Survival In Patients With Liver Metastasis

March 31, 2006

Obese Men More Likely To Have Aggressive Tumors

February 27, 2004